Oncology Today with Dr Neil Love

Épisodes

• 
  For Oncology Nurses: Ovarian Cancer — Proceedings from the 2026 Annual ONS Congress 23.07.2026 1h 30min

  Featuring perspectives from Dr Bradley J Monk, Dr David M O’Malley, Ms Kathryn M Schlenker and Ms Jaclyn Shaver, moderated by Dr O’Malley, including the following topics: Introduction (00:00)Overview of Ovarian Cancer (OC) (2:12)Role of PARP Inhibitors in Advanced OC (4:56)Current and Potential Future Role of Mirvetuximab Soravtansine in OC (28:45)Role of Relacorilant in Advanced OC (57:08)Utility of Immune Checkpoint Inhibition in Advanced OC (1:14:12)NCPD information and select publications
• 
  Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting 22.07.2026 1h 57min

  Featuring perspectives from Dr Melissa Alsina, Dr Hans Lee, Dr Sagar Lonial and Dr Paul G Richardson, moderated by Dr Lonial, including the following topics:Introduction (0:00)Integrating Bispecific Antibodies into the Management of Relapsed/Refractory (R/R) Multiple Myeloma (MM) — Dr Lee (1:45)Current Utility of Antibody-Drug Conjugates for MM — Dr Lonial (33:55)Potential Role of Cereblon E3 Ligase Modulators in Therapy for MM — Dr Richardson (59:42)Chimeric Antigen Receptor T-Cell Therapy for R/R MM — Dr Alsina (1:30:24)CME information and select publications
• 
  EGFR-Mutated Non-Small Cell Lung Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting 21.07.2026 1h 57min

  Featuring perspectives from Dr Sarah B Goldberg, Dr Jonathan Goldman, Dr Joel W Neal, Dr Antonio Passaro and Dr Jacob Sands, moderated by Dr Sands, including the following topics:Introduction (00:00)Evolving First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) — Prof Passaro (2:27)EGFR-Targeted Therapeutic Strategies for Relapsed EGFR-Mutant NSCLC — Dr Neal (36:08)Utility of TROP2-Targeted Antibody-Drug Conjugates in the Management of EGFR-Mutant NSCLC — Dr Sands (56:16)Emerging Role of Bispecific Antibody-Based Approaches for EGFR-Mutated NSCLC — Dr Goldman (1:19:08)Tolerability Considerations with the Use of Available and Emerging Therapies for EGFR-Mutated NSCLC — Dr Goldberg (1:38:46)CME information and select publications
• 
  Endometrial Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting 20.07.2026 1h 29min

  Featuring perspectives from Dr Floor J Backes, Dr Brian M Slomovitz and Dr Shannon N Westin, moderated by Dr Westin, including the following topics:Introduction (00:00)Current Up-Front Chemoimmunotherapeutic Approaches for Advanced Endometrial Cancer (EC) — Dr Backes (1:50)Current and Future Role of Anti-PD-1/PD-L1 Antibodies in Combination with Systemic Therapies Beyond Chemotherapy for Advanced EC — Dr Westin (33:15)Promising Agents Under Investigation for EC — Dr Slomovitz (1:01:41)CME information and select publications
• 
  HER2-Positive Metastatic Breast Cancer — An Interview with Prof Dr Sibylle Loibl on First-Line and Maintenance Therapy 17.07.2026 46min

  Featuring an interview with Prof Dr Sibylle Loibl, including the following topics:Perspectives on overall survival gains achieved over the years for patients with metastatic breast cancer (mBC) (0:00)Previous treatment and patient outcomes in the DESTINY-Breast09 trial of trastuzumab deruxtecan (T-DXd) with or without pertuzumab (5:35)Role of endocrine therapy in the treatment of hormone receptor-positive, HER2-positive mBC (8:01)Targeting the PI3K signaling pathway in HER2-positive mBC (11:08)Contraindications for T-DXd; T-DXd-associated gastrointestinal toxicities and interstitial lung disease (13:53)Optimal duration of and therapeutic partner for T-DXd as first-line maintenance therapy for patients with HER2-positive mBC (20:44)Case: A woman in her early 40s with metastatic relapse of HER2-positive breast cancer 2 years after completing neoadjuvant and adjuvant therapy (26:54)Role of exercise and weight control in the management of breast cancer; effect of pregnancy on the breast tumor immune environment (40:03)CME information and select publications
• 
  For Oncology Nurses: Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia — Proceedings from the 2026 Annual ONS Congress 16.07.2026 1h 58min

  Featuring perspectives from Dr Farrukh T Awan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, moderated by Dr Kahl, including the following topics:Introduction: Biology of Non-Hodgkin Lymphoma (NHL) (00:00)Current Role of CD20 x CD3 Bispecific Antibodies in NHL (4:49)Role of Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma (DLBCL) (27:48)Optimal Application of Loncastuximab Tesirine for Patients with DLBCL and Follicular Lymphoma (41:43)Role of Bruton Tyrosine Kinase (BTK) Inhibitors Alone or with Anti-CD20 Antibodies for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) (1:00:43)Combining BTK Inhibitors with Bcl-2 Inhibitors (1:31:15)Current and Future Role of Noncovalent BTK Inhibitors in CLL (1:41:30)CME information and select publications
• 
  Ovarian Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting 15.07.2026 2h 1min

  Featuring perspectives from Dr Ramez N Eskander, Dr Ursula Matulonis, Dr Kathleen N Moore, Dr Alexander B Olawaiye and Dr David M O'Malley, moderated by Dr Moore, including the following topics:Introduction (00:00)Current Role of PARP Inhibitors in the Management of Advanced Ovarian Cancer (OC) — Prof Eskander (2:40)Strategies Targeting Folate Receptor Alpha in Advanced OC — Dr Matulonis (27:41)Other Approved and Promising Investigational Antibody-Drug Conjugates for Advanced OC — Dr Moore (52:12)Other Novel Agents and Strategies for Advanced OC — Dr O'Malley (1:14:35)Diagnosis and Management of Adverse Events Associated with Common Therapies for Advanced OC — Dr Olawaiye (1:39:39)CME information and select publications
• 
  HER2-Altered Non-Small Cell Lung Cancer — Rapid Case Review 14.07.2026 27min

  Featuring an interview with Dr Mark Jeng and Dr Joshua K Sabari, including the following topics:Case: A woman in her late 90s with recurrent HER2-mutant metastatic non-small cell lung cancer (NSCLC) receives third-line zongertinib (0:00)Case: A woman in her early 60s with multiregimen-recurrent HER2-mutant metastatic NSCLC experiences a response to zongertinib (8:07)Case: A man in his mid 80s experiences metastatic recurrence after resection of PD-L1-positive, HER2-mutant metastatic NSCLC (17:50)CME information and select publications
• 
  Localized HR-Positive Breast Cancer — Year in Review Series on Relevant New Datasets and Advances 13.07.2026 58min

  Featuring perspectives from Dr Harold J Burstein and Dr Joyce O’Shaughnessy, including the following topics:Introduction: ODAC — April 30, 2026 (00:00)Adjuvant CDK4/6 Inhibitors (13:03)Adjuvant Oral Selective Estrogen Receptor Degraders (21:53)Premenopausal Patients (30:52)Duration of Adjuvant Endocrine Treatment (38:44)Genomic Predictors of Chemotherapy Benefit (47:19)Neoadjuvant Treatment (55:13)CME information and select publications
• 
  Endometrial Cancer — Microlearning Activity 2: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women’s Cancer 12.07.2026 15min

  Featuring perspectives from Dr Floor J Backes, Dr Matthew A Powell and Dr Ritu Salani, moderated by Dr Salani, including the following topics:Case: A woman in her late 60s presents with mismatch repair-deficient metastatic endometrial cancer(00:00)Perspectives on neoadjuvant immunotherapy for microsatellite instability-high endometrial cancer (06:25)CME information and select publications
• 
  Nonmetastatic Non-Small Cell Lung Cancer — An Interview with Dr Jamie E Chaft 11.07.2026 59min

  Featuring an interview with Dr Jamie E Chaft, including the following topics: Case: A man in his early 70s with a 40 to 50 pack-year history of smoking and cT2bN1 squamous cell carcinoma of the lung with PD-L1 60% treated with induction therapy and surgery (00:00)Available clinical data with immunotherapy in the neoadjuvant, perioperative and adjuvant settings (07:45)Factors in the selection of adjuvant immunotherapy, including circulating tumor DNA (11:39)Evolving approaches to management, including systemic therapy, surgery and radiation therapy techniques (19:28)Case: A woman in her early 60s with nonmetastatic non-small cell lung cancer (NSCLC) and an EGFR exon 19 deletion who is enrolled in the NeoADAURA study (24:03)Importance of clinical trials in the adjuvant setting (33:02)Data surrounding treatment in the neoadjuvant setting; key implications of the NeoADAURA study (35:41)Case: A man in his late 60s with a history of smoking and Stage III T4N3 NSCLC not otherwise specified with low PD-L1 expression, high tumor mutation burden, microsatellite stability and an STK11 mutation (41:34)Selecting patients for the NeoADAURA study treatment approach; deciding between chemoimmunotherapy and chemoradiation therapy (51:01)CME information and select publications
• 
  Endometrial Cancer — Microlearning Activity 1: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women’s Cancer 10.07.2026 11min

  Featuring perspectives from Dr Floor J Backes, Dr Matthew A Powell and Dr Ritu Salani, moderated by Dr Salani, including the following topics:Case: A woman in her late 70s with de novo metastatic mismatch repair-proficient metastatic endometrioid endometrial cancer (00:00)Molecular analyses in the assessment and management of endometrial cancer (07:33)CME information and select publications
• 
  Novel Therapies for Non-Hodgkin Lymphoma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting 09.07.2026 1h 57min

  Featuring perspectives from Dr Christopher Flowers, Dr Matthew Lunning, Dr Sonali M Smith and Dr Brad S Kahl, moderated by Dr Kahl, including the following topics:Rational Incorporation of CD79b-Targeted Antibody-Drug Conjugates into the Management of Newly Diagnosed and Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Flowers (00:00)Clinical Utility of CD19-Directed Monoclonal Antibodies in the Treatment of DLBCL and Follicular Lymphoma (FL) — Dr Smith (31:41)Optimal Use of CD19-Directed Antibody-Drug Conjugates for R/R DLBCL and FL — Dr Lunning (01:03:23)Current and Future Role of Bruton Tyrosine Kinase Inhibition in Therapy for Non-Hodgkin Lymphoma — Dr Kahl (01:26:48)CME information an d select publications
• 
  Antibody-Drug Conjugates in the Management of Breast Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting 08.07.2026 2h

  Featuring perspectives from Prof Giuseppe Curigliano, Prof Rebecca A Dent, Dr Erika Hamilton, Prof Nadia Harbeck and Dr Hope S Rugo, moderated by Dr Rugo, including the following topics:Introduction (00:00)Evolving Role of Antibody-Drug Conjugates (ADCs) in the Management of Metastatic Triple-Negative Breast Cancer — Prof Dent (02:57)Integrating ADCs into the Management of HER2-Positive Metastatic Breast Cancer (mBC) — Prof Curigliano (29:01)Role of ADCs in the Management of Endocrine-Resistant Hormone Receptor-Positive mBC — Dr Rugo (52:36)Emerging Utility of ADCs for Localized Breast Cancer — Prof Harbeck (01:14:36)Tolerability Considerations with ADCs for Breast Cancer — Dr Hamilton (01:38:10)CME information and select publications
• 
  Endometrial Cancer — An Interview with Dr Floor J Backes 07.07.2026 56min

  Featuring an interview with Dr Floor J Backes, including the following topics:Overview of the treatment landscape of endometrial cancer (00:00)Immunotherapy for advanced endometrial cancer (03:58)Contraindications for immunotherapy (18:15)PARP inhibitors for endometrial cancer (20:12)Management of localized endometrial cancer (28:23)Novel strategies under investigation for endometrial cancer (42:27)CME information and select publications
• 
  For Oncology Nurses: Strategies to Safely and Effectively Implement Antibody-Drug Conjugates — Proceedings from the 2026 Annual ONS Congress 06.07.2026 1h 28min

  Featuring perspectives from Ms Courtney Arn, Ms Jamie Carroll, Dr Edward B Garon, Dr Heather McArthur and Dr Kathleen N Moore, moderated by Dr Moore, including the following topics:Introduction (0:00)Overview of Antibody-Drug Conjugates (ADCs) (2:07)Current and Future Role of HER2-Targeted ADCs for Breast Cancer (6:23)Currently Available ADCs for Gynecologic Cancer Management (26:37)Currently Available ADCs for Lung Cancer Management (44:07)Current and Future Role of TROP2-Targeted ADCs for Metastatic Breast Cancer (56:55)Other ADCs That May Soon Reach the Clinic for Advanced Gynecologic Cancers (1:15:07)Promising Investigational Strategies Employing ADCs for Lung Cancer (1:25:01)NCPD information and select publications
• 
  Androgen Deprivation Therapy for Prostate Cancer — An Interview with Dr Rana R McKay 02.07.2026 35min

  Featuring an interview with Dr Rana R McKay, including the following topics:Prostate Cancer Working Group (PCWG4) revised terminology (0:00)Cardiovascular effects associated with GnRH agonists versus antagonists; mechanism of action (2:17)Combination therapy using relugolix; factors affecting persistence and adherence to GnRH agents (12:06)Takeaways from the Phase III EMBARK study (19:36)Use of CAR (chimeric antigen receptor) T-cell therapy and T-cell engagers (27:20)Potential role of circulating tumor DNA minimal residual disease testing; use of olaparib/radium-223 (29:24)CME information and select publications
• 
  For Oncology Nurses: Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Proceedings from the 2026 Annual ONS Congress 01.07.2026 1h 30min

  Featuring perspectives from Dr Alexandra Drakaki, Ms Krisztina Emodi, Dr Terence Friedlander and Ms Margarita Huober, moderated by Dr Friedlander, including the following topics: Introduction: Basic Biology of Nonmetastatic Urothelial Bladder Cancer (UBC) (0:00)Systemic Therapy for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer (MIBC) (13:35)Evolving Approach to Systemic Therapy for Cisplatin-Ineligible Patients with MIBC (37:13)Immune Checkpoint Inhibitors in Non-Muscle-Invasive Bladder Cancer (58:55)Novel Intravesical Therapies for Nonmetastatic UBC (1:10:20)NCPD information and select publications
• 
  Targeted Therapies for Non-Small Cell Lung Cancer — Fifth Annual National General Medical Oncology Summit 30.06.2026 50min

  Featuring perspectives from Dr Lyudmila Bazhenova and Dr Corey J Langer, including the following topics: Introduction (0:00)Therapeutic Approaches Targeting HER2 and RET — Dr Bazhenova (9:09)Therapeutic Approaches Targeting ALK and ROS1 — Dr Langer (31:56)CME information and select publications
• 
  HR-Positive Breast Cancer — Fifth Annual National General Medical Oncology Summit 29.06.2026 1h 39min

  Featuring perspectives from Dr Erika Hamilton, Dr Jane Lowe Meisel, Dr Joyce O’Shaughnessy and Dr Seth Wander, including the following topics: Introduction (0:00)Current and Future Management of HR-Positive, HER2-Negative Localized Breast Cancer — Dr Meisel(2:40)Optimizing First-Line Therapy for Patients with HR-Positive Metastatic Breast Cancer (mBC) — Dr Hamilton (36:57)Current and Future Role of Oral Selective Estrogen Receptor Degraders for Progressive HR-Positive mBC — Dr Wander (58:18)Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive mBC — Dr O'Shaughnessy (1:18:00)CME information and select publications